Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377776 | 1.00 | NFE2L2 (0.36) | NFE2L2POLBKDM4EL3MBTL1HDAC6 | |
| SCHEMBL15944537 | 0.91 | NFE2L2 (0.33) | NFE2L2POLBKDM4EL3MBTL1HDAC6 | |
| SCHEMBL15334372 | 0.85 | NFE2L2 (0.34) | NFE2L2POLBKDM4EL3MBTL1HDAC6 | |
| SCHEMBL35943 | 0.79 | HDAC6 (0.36) | KDM4EL3MBTL1HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL45935 | 0.79 | DEGS1 (0.35) | PTGS1 | |
| SCHEMBL4554960 | 0.79 | — | — | |
| SCHEMBL17322362 | 0.77 | NFE2L2 (0.38) | NFE2L2POLBKDM4EL3MBTL1HDAC6 | |
| SCHEMBL5706356 | 0.76 | HDAC6 (0.39) | NFE2L2POLBKDM4EL3MBTL1HDAC6 | |
| SCHEMBL7642605 | 0.76 | POLB (0.35) | NFE2L2POLBKDM4EL3MBTL1HDAC6 | |
| SCHEMBL14553395 | 0.76 | KDM4E (0.34) | KDM4ESMN1; SMN2NPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1424 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658652-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2024163626-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | claimed |
| EP-3694853-B1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | ARRAY BIOPHARMA INC (US) | 2023-05-17 | — | — | EP | claimed |
| EP-3694853-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | Array BioPharma Inc. (US) | 2020-08-19 | — | — | EP | claimed |
| WO-2019075092-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | EARY CHARLES TODD (US) | 2019-04-18 | — | — | WO | claimed |
| US-20190106438-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2019-04-11 | — | — | US | claimed |
| EP-3013848-B1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2018-10-17 | — | — | EP | claimed |
| US-9556218-B2 | Process for the preparation of abiraterone and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2017-01-31 | — | — | US | claimed |
| EP-3013848-A2 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | Scinopharm Taiwan, Ltd. (CN) | 2016-05-04 | — | — | EP | claimed |
| US-20160102159-A1 | Olefin Polymerization Catalyst and a Combined Catalyst Containing the Same | PETROCHINA COMPANY LIMITED (CN) | 2016-04-14 | — | — | US | claimed |
| US-20150005489-A1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (CN) | 2015-01-01 | — | — | US | claimed |
| WO-2014207567-A2 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2014-12-31 | — | — | WO | claimed |
| US-8470941-B2 | Catalyst for homopolymerizing and copolymerizing propylene and its preparation and use | PETROCHINA COMPANY LIMITED (CN) | 2013-06-25 | — | — | US | claimed |
| US-8404789-B2 | Olefin polymerization catalyst and preparation method and use thereof | PETROCHINA COMPANY LIMITED (CN) | 2013-03-26 | — | — | US | claimed |
| EP-2159232-B1 | OLEFIN POLYMERIZATION CATALYST AND PREPARATION METHOD AND USE THEREOF | PETROCHINA CO LTD (CN) | 2012-11-21 | — | — | EP | claimed |
| US-20110207900-A1 | CATALYST FOR HOMOPOLYMERIZING AND COPOLYMERIZING PROPYLENE AND ITS PREPARATION AND USE | PETROCHINA COMPANY LIMITED (CN) | 2011-08-25 | — | — | US | claimed |
| EP-2345675-A1 | A CATALYST FOR HOMOPOLYMERIZING AND COPOLYMERIZING PROPYLENE AND ITS PREPARATION AND USE | Petrochina Company Limited (CN) | 2011-07-20 | — | — | EP | claimed |
| US-20100184930-A1 | OLEFIN POLYMERIZATION CATALYST AND PREPARATION METHOD AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2010-07-22 | — | — | US | claimed |
| EP-2159232-A1 | OLEFIN POLYMERIZATION CATALYST AND PREPARATION METHOD AND USE THEREOF | Petrochina Company Limited (CN) | 2010-03-03 | — | — | EP | claimed |
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731216-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720050-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709712-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | Blueprint Medicines Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4658652-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250289781-A1 | TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2025-09-18 | — | — | US | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| EP-4615454-A1 | SOS1 INHIBITORS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-09-17 | — | — | EP | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO LLC | 2025-08-21 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| WO-2025137507-A1 | SOS1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| WO-2025094700-A1 | TRIFLUOROMETHANESULFONATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND | 学校法人神戸薬科大学 | 2025-05-08 | — | — | WO | disclosed |
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025076476-A2 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250092024-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2025-03-20 | — | — | US | disclosed |
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-06 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4504733-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-12216113-B2 | Method for preparing analysis sample, analysis method, and kit for preparing analysis sample | SHIMADZU CORPORATION (JP) | 2025-02-04 | — | — | US | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| EP-4493556-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024261329-A1 | HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024249672-A1 | PROCESS OF PREPARING HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024233900-A1 | GSK3A INHIBITORS AND METHODS OF USE THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024229317-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20240360109-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-12077526-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-03 | — | — | US | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024163626-A2 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| EP-4382525-A1 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240182426-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2024-06-06 | — | — | US | disclosed |
| WO-2024110851-A1 | INHIBITORS OF ROCK2 | GRAVITON BIOSCIENCE BV (NL) | 2024-05-30 | — | — | WO | disclosed |
| US-11992489-B2 | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| CN-113874015-B | Thienopyridine inhibitors of RIPK2 | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| WO-2024083168-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4330249-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| EP-3836928-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4313963-A1 | PHENYL- [1, 3] DIOXOLO [4, 5-C] PYRIDINYL-PHENYL-, PHENYL- [1, 3] DIOXOLO [4, 5-C] PYRIDINYL-HETEROARYL-, OR PHENYL- [1, 3] DIOXOLO [4, 5-C] PYRIDINYL-PIPERIDINYL-METHYL-OXETANYLMETHYL-1H-BENZO [D] IMIDAZOLE-CARBOXYLIC ACID DERIVATIVES AND METHODS OF USING SAME | Eccogene Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3897630-B1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORP (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20240002359-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| CN-117222631-A | Phenyl- [1,3] dioxolo [4,5-C ] pyridinyl-phenyl-, phenyl- [1,3] dioxolo [4,5-C ] pyridinyl-heteroaryl-or phenyl- [1,3] dioxolo [4,5-C ] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1H-benzo [ D ] imidazole-carboxylic acid derivatives and methods of use thereof | 诚益生物(美国)公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11807651-B2 | Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023207881-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| EP-4255429-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3750883-B1 | AMINOALKYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023178099-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-111148735-B | Nitrogen-containing heteroaryl compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20230212193-A1 | CRYSTALLINE RET INHIBITOR | ELI LILLY AND COMPANY | 2023-07-06 | — | — | US | disclosed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230203081-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023107870-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-3694853-B1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | ARRAY BIOPHARMA INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230121578-A1 | SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1 | SELVITA SERVICES SP. Z O.O. (PL) | 2023-04-20 | — | — | US | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| US-11603367-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2023-03-14 | — | — | US | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023023474-A1 | TR-BETA MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-4136090-A1 | CRYSTALLINE RET INHIBITOR | Loxo Oncology, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3693358-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-02-22 | — | — | EP | disclosed |
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3759085-B1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11512053-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
| US-11512090-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
| WO-2022232459-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-11-03 | — | — | WO | disclosed |
| US-20220348564-A1 | PHENYL-[1,3]DIOXOLO[4,5-C]PYRIDINYL-PHENYL-, PHENYL-[1,3]DIOXOLO[4,5-C]PYRIDINYL-HETEROARYL-, OR PHENYL-(1,3)DIOXO[4,5-C]PYRIDINYL-PIPERIDINYL-METHYL-OXETANYLMETHYL-1H-BENZO[D]IMIDAZOLE-CARBOXYLIC ACID DERIVATIVES AND METHODS OF USING SAME | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2022-11-03 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| EP-4076668-A1 | COMPOSITION AND METHOD FOR TREATING DERMATOLOGICAL DISORDERS USING RETINAMIDES | University of Maryland, Baltimore (US) | 2022-10-26 | — | — | EP | disclosed |
| US-11478478-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-10-25 | — | — | US | disclosed |
| US-11479539-B2 | Small molecule modulators of the BTB domain of Keap1 | MEDIMMUNE LIMITED (GB) | 2022-10-25 | — | — | US | disclosed |
| US-20220332721-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2022199661-A1 | PHENYL- [1, 3] DIOXOLO [4, 5-C] PYRIDINYL-PHENYL-, PHENYL- [1, 3] DIOXOLO [4, 5-C] PYRIDINYL-HETEROARYL-, OR PHENYL- [1, 3] DIOXOLO [4, 5-C] PYRIDINYL-PIPERIDINYL-METHYL-OXETANYLMETHYL-1H-BENZO [D] IMIDAZOLE-CARBOXYLIC ACID DERIVATIVES AND METHODS OF USING SAME | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2022-09-29 | — | — | WO | disclosed |
| US-11440896-B2 | Aminoalkyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-09-13 | — | — | US | disclosed |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022119888-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | US | disclosed |
| EP-3511323-B1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-03-02 | — | — | EP | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3929194-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3924058-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3924054-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2021-12-22 | — | — | EP | disclosed |
| US-20210380609-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | ARRAY BIOPHARMA INC. | 2021-12-09 | — | — | US | disclosed |
| CN-113710656-A | Substituted bicyclic compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE, LLC | 2021-11-04 | — | — | US | disclosed |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE, LLC | 2021-11-04 | — | — | US | disclosed |
| WO-2021211380-A1 | CRYSTALLINE RET INHIBITOR | LOXO ONCOLOGY, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| CN-113490528-A | 3- (1-oxo-5- (piperidine-4-yl) isoindoline-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3883945-A1 | C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3880675-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | Debiopharm International SA (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-20210276999-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2021-09-09 | — | — | US | disclosed |
| US-11111229-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-113272302-A | Antibiotic compounds, process for their manufacture, pharmaceutical compositions containing them and their use | 德彪药业国际股份公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3630752-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3836928-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-20210161896-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210164989-A1 | METHOD FOR PREPARING ANALYSIS SAMPLE, ANALYSIS METHOD, AND KIT FOR PREPARING ANALYSIS SAMPLE | SHIMADZU CORPORATION (JP) | 2021-06-03 | — | — | US | disclosed |
| CN-107074820-B | GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3812767-A1 | METHOD FOR PREPARING ANALYSIS SAMPLE, ANALYSIS METHOD, AND KIT FOR PREPARING ANALYSIS SAMPLE | SHIMADZU CORPORATION (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| EP-3799872-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR USE AS BET INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210094931-A1 | SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1 | MEDIMMUNE LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| CN-112457301-A | Novel GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20210046073-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20210040057-A1 | AMINOALKYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
| CN-107428682-B | Amide derivatives, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| EP-3071203-B1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3750883-A1 | AMINOALKYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-3746075-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3368539-B1 | SUBSTITUTED INDAZOLE COMPOUNDS AS ROR GAMMA T INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10851101-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200369642-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200308194-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2020-10-01 | — | — | US | disclosed |
| EP-2970132-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3309152-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10752596-B2 | Nitrogen-containing heteroaryl compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2020-08-25 | — | — | US | disclosed |
| WO-2020165833-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020167706-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-3694853-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | Array BioPharma Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10745419-B2 | Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200255403-A1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3693358-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2020-08-12 | — | — | EP | disclosed |
| CN-111491922-A | Small molecule modulators of the BTB domain of Keap1 | 免疫医疗有限公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-3368516-B1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3345909-B1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3388423-B1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL (JP) | 2020-05-27 | — | — | EP | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
| EP-3406252-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| CN-111148735-A | Nitrogen-containing heteroaryl compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2020-05-12 | — | — | CN | disclosed |
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3630752-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10611750-B2 | Tetrahydroquinoline compositions as bet bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10583139-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| EP-2585462-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| WO-2020036837-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3601272-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | Astex Therapeutics Limited (GB) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678462-A | Isoindolinone inhibitors of MDM2-P53 interaction and methods of making the same | 阿斯泰克斯治疗有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-2933246-B1 | VERSATILE AND FUNCTIONALISED INTERMEDIATES FOR THE SYNTHESIS OF VITAMIN D AND NOVEL VITAMIN D DERIVATIVES | ENDOTHERM GMBH (DE) | 2020-01-08 | — | — | EP | disclosed |
| CN-110627770-A | Tetrahydroquinoline compositions as BET bromodomain inhibitors | 福马疗法公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190352262-A1 | New Pleuromutilin Antibiotic Compounds, Compositions and Methods of Use and Synthesis | UNIV YALE (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190276472-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
| US-10399949-B2 | NK1 receptor antagonist | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019148132-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| EP-3511323-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2019-07-17 | — | — | EP | disclosed |
| US-10344000-B2 | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10336722-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190152926-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-3484879-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2019-05-22 | — | — | EP | disclosed |
| EP-3483167-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10287272-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| EP-3057958-B1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-05-01 | — | — | EP | disclosed |
| WO-2019075092-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | EARY CHARLES TODD (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106438-A1 | PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3074402-B1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180346453-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-12-06 | — | — | US | disclosed |
| WO-2018222795-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3406252-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-20180312489-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-11-01 | — | — | US | disclosed |
| EP-3013337-B1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180303831-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-10-25 | — | — | US | disclosed |
| US-20180305320-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-10-25 | — | — | US | disclosed |
| EP-2970127-B1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-10-24 | — | — | EP | disclosed |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3388423-A1 | NK1 RECEPTOR ANTAGONIST | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-10-17 | — | — | EP | disclosed |
| EP-3013848-B1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2018-10-17 | — | — | EP | disclosed |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-09 | — | — | US | disclosed |
| WO-2018178691-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| US-10081603-B2 | Arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3368516-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3368539-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3096754-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-10034881-B2 | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | US | disclosed |
| EP-2721029-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-3345909-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2968288-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2812004-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | disclosed |
| WO-2018106643-A1 | HETEROCYCLIC AZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9994508-B2 | Versatile and functionalised intermediates for the synthesis of vitamin D and novel vitamin D derivatives | ENDOTHERM GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| EP-3309152-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018030550-A1 | HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | WO | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| EP-3256464-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| CN-104640869-B | Imidazo thiadiazoles and Imidazopyridazine derivative as proteinase activated receptors 4 (PAR4) inhibitor for treating platelet aggregation | 百时美施贵宝公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320886-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170305900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-10-26 | — | — | US | disclosed |
| EP-2970323-B1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| EP-2940000-B1 | PROCESS FOR PREPARING METHYL ACETATE | DALIAN INST CHEMICAL PHYSICS CAS (CN) | 2017-10-18 | — | — | EP | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-2516417-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9777019-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9765074-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| EP-2814834-B1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-09-13 | — | — | EP | disclosed |
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2956458-B1 | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2956458-B1 | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| EP-2758377-B1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9714255-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714255-B2 | Cortistatin analogues and syntheses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-25 | — | — | US | disclosed |
| EP-2956459-B1 | SUBSTITUTED PHENYL-HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2956459-B1 | SUBSTITUTED PHENYL-HEXAHYDROPYRANO[3,4-D][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170189401-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190734-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Selcia Ltd. (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174624-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9676759-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2758389-B1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9670221-B2 | Furopyridines as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9670219-B2 | Tetrahydrooxepinopyridine compound | ASTELLAS PHARMA INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20170144973-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS | Takenda Pharmaceutical Company Limited (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9650343-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-9642889-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642889-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121315-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-04 | — | — | US | disclosed |
| WO-2017075182-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075178-A1 | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | disclosed |
| EP-2882739-B1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-05-03 | — | — | EP | disclosed |
| US-9637456-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9630924-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9617259-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9598374-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| US-9586945-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586942-B2 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586968-B2 | Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586968-B2 | Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586968-B2 | Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | disclosed |
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9573903-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2852590-B1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9556218-B2 | Process for the preparation of abiraterone and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2017-01-31 | — | — | US | disclosed |
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | US | disclosed |
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9493441-B2 | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2877471-B1 | SPIRO-FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9481639-B2 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | PARATEK PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481639-B2 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | PARATEK PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3074402-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9453023-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2401265-B1 | DERIVATIVES OF 1-PYRI(MID)IN-2-YL-PYRAZOLE-4-CARBOXYLIC ACID WHICH ARE USEFUL FOR THERAPY OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9440226-B2 | Method for preparing methyl acetate | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-13 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| EP-2758050-B1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-3057960-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-24 | — | — | EP | disclosed |
| EP-3057958-A1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| WO-2016128456-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | WO | disclosed |
| EP-2682386-B1 | NOVEL VITAMIN D RECEPTOR MODULATOR WITH PARTIAL AGONIST ACTIVITY | UNIV NIHON (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220633-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-3045449-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS | Paratek Pharmaceuticals, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9394282-B2 | Pyrazole carboxamides as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394295-B2 | Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-19 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2632551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160176822-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176873-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176872-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9365563-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365563-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160159818-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3013848-A2 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | Scinopharm Taiwan, Ltd. (CN) | 2016-05-04 | — | — | EP | disclosed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9315518-B2 | Imidazopyridin-2-one derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315518-B2 | Imidazopyridin-2-one derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315518-B2 | Imidazopyridin-2-one derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160102159-A1 | Olefin Polymerization Catalyst and a Combined Catalyst Containing the Same | PETROCHINA COMPANY LIMITED (CN) | 2016-04-14 | — | — | US | disclosed |
| US-9301953-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301953-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301953-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9296760-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-29 | — | — | US | disclosed |
| US-9296759-B2 | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2016044626-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-9290454-B2 | Substituted isoquinolines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290454-B2 | Substituted isoquinolines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| EP-2794564-B1 | STRIGOLACTAM DERIVATIVES AS PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-20160046561-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160031876-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160024091-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-01-28 | — | — | US | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20160016908-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20160016966-A1 | FUROPYRIDINES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-21 | — | — | US | disclosed |
| EP-2968288-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970127-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-01-20 | — | — | EP | disclosed |
| US-9233981-B1 | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233981-B1 | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20160002169-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-20150376207-A1 | Substituted Phenyl Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376207-A1 | Substituted Phenyl Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376201-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-31 | — | — | US | disclosed |
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20150361132-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361132-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| WO-2015189117-A1 | HETEROBICYCLICALLY SUBSTITUTED 4-OXOBUTANE ACID DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-17 | — | — | WO | disclosed |
| US-20150353498-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353498-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9206198-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150344421-A1 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives | ENDOTHERM GMBH (DE) | 2015-12-03 | — | — | US | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9192612-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9192612-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2940000-A1 | PROCESS FOR PREPARING METHYL ACETATE | Dalian Institute Of Chemical Physics, Chinese Academy of Sciences (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-20150298108-A1 | METHOD FOR PREPARING METHYL ACETATE | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2933246-A1 | VERSATILE AND FUNCTIONALISED INTERMEDIATES FOR THE SYNTHESIS OF VITAMIN D AND NOVEL VITAMIN D DERIVATIVES | Endotherm GmbH (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-9131688-B2 | Strigolactam derivatives as plant growth regulating compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9127019-B2 | Cortistatin analogues and synthesis thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127019-B2 | Cortistatin analogues and synthesis thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-09-08 | — | — | US | disclosed |
| US-9115151-B2 | Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof | ABBVIE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150225424-A1 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | US | disclosed |
| US-20150224110-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150224110-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2015-08-13 | — | — | US | disclosed |
| EP-2903969-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-9090627-B2 | Batrachotoxin analogues, compositions, uses, and preparation thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062092-B2 | Macrocyclic inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166563-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| EP-2882739-A1 | NEW ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| WO-2015077905-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015077905-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080988-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2877471-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-06-03 | — | — | EP | disclosed |
| US-9045499-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045499-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| WO-2015074064-A2 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| US-9023858-B2 | Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| US-9018194-B2 | Vitamin D receptor modulators with partial agonist activity | Nibon University (JP) | 2015-04-28 | — | — | US | disclosed |
| WO-2015055770-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111875-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111867-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | US | disclosed |
| WO-2015055771-A1 | AMINOTETRALINE AND AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-04-23 | — | — | US | disclosed |
| US-9012634-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN R&D IRELAND (IE) | 2015-04-21 | — | — | US | disclosed |
| US-9012446-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012433-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012433-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150099729-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2855489-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8993766-B2 | Method of preparing tetrabenazine and dihydrotetrabenazine | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-03-31 | — | — | US | disclosed |
| US-8993619-B2 | Cyclic bridgehead ether DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| EP-2569280-B1 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962608-B2 | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8946195-B2 | Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005489-A1 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2014207567-A2 | PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2014-12-31 | — | — | WO | disclosed |
| EP-2814834-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | Bristol-Myers Squibb Company (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2812004-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140364426-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364426-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER (US) | 2014-12-11 | — | — | US | disclosed |
| US-8906889-B2 | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350002-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8895583-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889690-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889690-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140336052-A1 | STRIGOLACTAM DERIVATIVES AS PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2794564-A1 | STRIGOLACTAM DERIVATIVES AS PLANT GROWTH REGULATING COMPOUNDS | Syngenta Participations AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8865706-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865706-B2 | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds | PFIZER INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. | 2014-10-02 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| WO-2014150132-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014140076-A1 | 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275005-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275005-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275005-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-09-18 | — | — | US | disclosed |
| US-8829027-B2 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249185-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140243309-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| US-20140235641-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | INTERVET INC. | 2014-08-21 | — | — | US | disclosed |
| WO-2014125397-A1 | SUBSTITUTED PHENYL HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS | PFIZER INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| US-20140228356-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228356-A1 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds | PFIZER INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140228358-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| EP-2758389-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2758406-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2758051-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2758377-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2758050-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140206652-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | WUXI APPTECH (SHANGHAI) CO., LTD. (CN) | 2014-07-24 | — | — | US | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8759532-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140171418-A1 | Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-19 | — | — | US | disclosed |
| WO-2014089904-A1 | TRIAZINONE COMPOUNDS | ABBVIE INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140171410-A1 | Batrachotoxin Analogues, Compositions, Uses, and Preparation Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2742047-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | Janssen R&D Ireland (IE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2742044-A1 | ANTIBACTERIAL HOMOPIPERIDINYL SUBSTITUTED 3,4 DIHYDRO 1H [1,8]NAPHTHYRIDINONES | Janssen R&D Ireland (IE) | 2014-06-18 | — | — | EP | disclosed |
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-12 | — | — | US | disclosed |
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8735385-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735385-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735385-B2 | Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8716267-B2 | Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2721029-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697722-B2 | Nicotinic acetylcholine receptor modulators | SRI INTERNATIONAL (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2014053665-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680118-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| WO-2014023815-A1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-02-13 | — | — | WO | disclosed |
| US-20140038925-A1 | Novel Vitamin D Receptor Modulators with Partial Agonist Activity | NIHON UNIVERSITY (JP) | 2014-02-06 | — | — | US | disclosed |
| US-20140038954-A1 | Spiro-Amino-Imidazo-Fused Heterocyclic Compounds as Beta-secretase Modulators and Methods of Use | AMGEN INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038936-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-06 | — | — | US | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014015495-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018764-A1 | SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | WO | disclosed |
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637548-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637548-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637548-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2547686-B1 | AMINO-DIHYDROOXAZINE AND AMINO-DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA-SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| EP-2682386-A1 | NOVEL VITAMIN D RECEPTOR MODULATOR WITH PARTIAL AGONIST ACTIVITY | Nihon University (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8609690-B2 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2265616-B1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI PHARM INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8586574-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8575199-B2 | Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists | PURDUE PHARMA L.P. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575199-B2 | Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists | PURDUE PHARMA L.P. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130289058-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-10-31 | — | — | US | disclosed |
| WO-2013163241-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-1971595-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2135867-B1 | Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same | KOSAN BIOSCIENCES INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2013123019-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8513220-B2 | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513223-B2 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | PARATEK PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130210787-A1 | C-3 CYCLOALKENYL TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130210798-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-8507559-B2 | Cyclohexenyl modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130197227-A1 | METHOD OF PREPARING TETRABENAZINE AND DIHYDROTETRABENAZINE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-08-01 | — | — | US | disclosed |
| US-8497264-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-8476277-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476277-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2013092430-A1 | STRIGOLACTAM DERIVATIVES AS PLANT GROWTH REGULATING COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-8470941-B2 | Catalyst for homopolymerizing and copolymerizing propylene and its preparation and use | PETROCHINA COMPANY LIMITED (CN) | 2013-06-25 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2604598-A1 | TRPV1 antagonists and uses thereof | Purdue Pharma L.P. (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2604599-A1 | TRPV1 antagonists and uses thereof | Purdue Pharma LP (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8466288-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-18 | — | — | US | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2597095-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131050-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130102779-A1 | Substituted Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102779-A1 | Substituted Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| EP-2364306-B1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079325-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | ALLEN JENNIFER R (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013040863-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043962-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043964-A1 | ACYCLIC CYANOETHYLPYRAZOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013044092-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8404789-B2 | Olefin polymerization catalyst and preparation method and use thereof | PETROCHINA COMPANY LIMITED (CN) | 2013-03-26 | — | — | US | disclosed |
| EP-2569280-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065877-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065877-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065877-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-14 | — | — | US | disclosed |
| WO-2013026942-A1 | TUBULIN BINDING AGENTS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013021051-A1 | ANTIBACTERIAL HOMOPIPERIDINYL SUBSTITUTED 3,4 DIHYDRO 1H [1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013021052-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2547686-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20130018019-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012541-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8343955-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8338603-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2012174199-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324378-B2 | Prodrugs and conjugates of prenylation inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318718-B2 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318706-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2159232-B1 | OLEFIN POLYMERIZATION CATALYST AND PREPARATION METHOD AND USE THEREOF | PETROCHINA CO LTD (CN) | 2012-11-21 | — | — | EP | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2516417-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120264718-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142377-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012118154-A1 | NOVEL VITAMIN D RECEPTOR MODULATOR WITH PARTIAL AGONIST ACTIVITY | 学校法人日本大学 (JP) | 2012-09-07 | — | — | WO | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8242104-B2 | Benzoxazepin P13K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-8227467-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227467-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-1940401-B1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178560-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120108642-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2012-05-03 | — | — | US | disclosed |
| EP-1627869-B1 | Vanilloid receptor modulators | AJINOMOTO KK (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168827-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2401265-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-1441720-B1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402009-A1 | Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-8084616-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| WO-2011143150-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275595-A1 | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-8053438-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2011115928-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| EP-1436298-B1 | HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2011-09-21 | — | — | EP | disclosed |
| US-8022206-B2 | Furo[3,2-C]pyridines | OSI Pharmaceuticals, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2364306-A1 | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364308-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110213168-A1 | DEUTERATED VITAMIN D COMPOUNDS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2011-09-01 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207900-A1 | CATALYST FOR HOMOPOLYMERIZING AND COPOLYMERIZING PROPYLENE AND ITS PREPARATION AND USE | PETROCHINA COMPANY LIMITED (CN) | 2011-08-25 | — | — | US | disclosed |
| EP-2360154-A1 | DEUTERATED VITAMIN D COMPOUNDS | Universidade De Santiago De Compostela (ES) | 2011-08-24 | — | — | EP | disclosed |
| CN-102159531-A | Cyclohexenyl modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO | 2011-08-17 | — | — | CN | disclosed |
| US-20110190323-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190323-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2350068-A2 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011087776-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2345675-A1 | A CATALYST FOR HOMOPOLYMERIZING AND COPOLYMERIZING PROPYLENE AND ITS PREPARATION AND USE | Petrochina Company Limited (CN) | 2011-07-20 | — | — | EP | disclosed |
| EP-1432420-B1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110152324-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152324-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| EP-2318403-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2011-05-11 | — | — | EP | disclosed |
| EP-1140085-B1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PHIVCO UK LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1805160-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071192-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7910623-B2 | Synthesis of scabronines and analogues thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1901731-B1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7897611-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2281823-A2 | Anti-inflammatory and analgesic piperidine derivatives | Ajinomoto Co., Inc. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20110009485-A9 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2266947-A1 | Ester derivatives as competitive inhibitors of type II dehydroquinase enzyme | Universidad De Santiago De Compostela (ES) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265616-A1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010138901-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE | BIOGEN IDEC MA INC (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249072-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010099054-A2 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216840-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-7776861-B2 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776861-B2 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776861-B2 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| EP-2215061-A2 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7767684-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100184930-A1 | OLEFIN POLYMERIZATION CATALYST AND PREPARATION METHOD AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2010-07-22 | — | — | US | disclosed |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7754708-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010046445-A2 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683063-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2010023161-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010024930-A2 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-2159232-A1 | OLEFIN POLYMERIZATION CATALYST AND PREPARATION METHOD AND USE THEREOF | Petrochina Company Limited (CN) | 2010-03-03 | — | — | EP | disclosed |
| US-7659294-B2 | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists | MERCK & CO., INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7652024-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-2135867-A1 | Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same | Kosan Biosciences Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1562941-B1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | KOSAN BIOSCIENCES INC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2135868-A1 | TRANS-9, 10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | Kosan Biosciences Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1678172-B1 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1606255-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7608673-B2 | Organosilane compound and organosilica obtain therefrom | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2009-10-27 | — | — | US | disclosed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090258900-A1 | AMIDE DERIVATIVE | AJINOMOTO CO. INC (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-2098508-A1 | Cyclic derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009100282-A1 | FURO-AND THIENO[3,2-C] PYRIDINES | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-7572815-B2 | Amide derivative | AJINOMOTO CO., INC. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | MERCK SHARP & DOHME CORP. | 2009-08-06 | — | — | US | disclosed |
| US-20090186927-A1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | KOSAN BIOSCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186940-A1 | Synthesis of Scabronines and Analogues Thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2009-07-23 | — | — | US | disclosed |
| EP-2080757-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080757-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2009-07-22 | — | — | EP | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1858513-A4 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1867644-B1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO CELTIQUE SA (LU) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060260-A1 | Therapeutic agents useful for treating pain | Euro-Celtique S.A. (LU) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060260-A1 | Therapeutic agents useful for treating pain | Euro-Celtique S.A. (LU) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-07 | — | — | US | disclosed |
| WO-2009058120-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SRI INTERNATIONAL (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009055629-A2 | CYCLOHEXENEAMIDE DERIVATIVES AND THEIR USE AS TRPV1 ANTAGONIST | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-2040706-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009029849-A1 | PRODRUGS AND CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20090042954-A1 | 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| US-7482372-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1664026-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1664026-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008153858-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312193-A1 | Substituted Tetracycline Compounds for Treatment of Inflammatory Skin Disorders | PARATEK PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1940401-A4 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1862458-B1 | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1862458-B1 | Therapeutic agents useful for treating pain | EURO CELTIQUE SA (LU) | 2008-11-05 | — | — | EP | disclosed |
| EP-1983993-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1648879-B1 | HETEROARYL-TETRAHYDROPYRIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2008-10-22 | — | — | EP | disclosed |
| EP-1648879-B1 | HETEROARYL-TETRAHYDROPYRIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2008-10-22 | — | — | EP | disclosed |
| US-7439236-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | BHATTI BALWINDER | 2008-10-02 | — | — | US | disclosed |
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | TARGACEPT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1971602-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080227941-A1 | Organosilane compound and organosilica obtained therefrom | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080207693-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20080207693-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| EP-1613585-A4 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7402592-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| EP-1940401-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1219622-B1 | Pharmaceutical compositions for CNS and other disorders | PFIZER PROD INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-7384929-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7354951-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1901731-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080064742-A1 | Substituted Benzopyrans as Selective Estrogen Receptor-Beta Agonists | ELI LILLY AND COMPANY | 2008-03-13 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7329673-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080009520-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1867644-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2007-12-19 | — | — | EP | disclosed |
| EP-1867644-A1 | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain | EURO-CELTIQUE S.A. (LU) | 2007-12-19 | — | — | EP | disclosed |
| EP-1862458-A2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-12-05 | — | — | EP | disclosed |
| EP-1862458-A2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-12-05 | — | — | EP | disclosed |
| EP-1858513-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-7300928-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301028-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301028-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291611-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7273857-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007092364-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092364-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| EP-1631285-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-08-08 | — | — | EP | disclosed |
| EP-1631285-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2007-08-08 | — | — | EP | disclosed |
| EP-1551962-A4 | MITOTIC KINESIN BINDING SITE | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1805160-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7241796-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075749-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1802601-A1 | AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | Targacept, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JAIN NARESHKUMAR F | 2007-06-21 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070099904-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| EP-1613601-A4 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| EP-1515949-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7183445-B2 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-20070027159-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-01 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1740570-A2 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO., INC. | 2006-12-28 | — | — | US | disclosed |
| US-7153868-B2 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. | 2006-12-26 | — | — | US | disclosed |
| US-20060258707-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-11-16 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1631285-A4 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. | 2006-10-19 | — | — | US | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006098912-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099313-A2 | PHOSPHATE CONJUGATES OF PRENYLATION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205785-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-14 | — | — | US | disclosed |
| EP-1699775-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | Allergan, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060199799-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-09-07 | — | — | US | disclosed |
| EP-1696899-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060183904-A1 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| US-7087593-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1683794-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | Arena Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1678172-A2 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Targacept, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060134767-A1 | Mitotic kinesin binding site | MERCK & CO., INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060128755-A1 | Amide derivative | AJINOMOTO CO. INC (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20060128717-A1 | Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants | PURDUE PHARMA L.P. | 2006-06-15 | — | — | US | disclosed |
| EP-1664026-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060106050-A1 | Thrombin receptor antagonists | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060105997-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-7037920-B2 | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | SCHERING CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006044176-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1648879-A1 | HETEROARYL-TETRAHYDROPIPERIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | Euro-Celtique S.A. (LU) | 2006-04-26 | — | — | EP | disclosed |
| US-7026487-B2 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity | ALLERGAN, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060074243-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2006-04-06 | — | — | US | disclosed |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | BHATTI BALWINDER | 2006-04-06 | — | — | US | disclosed |
| WO-2006034089-A1 | AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | TARGACEPT, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0929554-B1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633692-A2 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| EP-1631285-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Euro-Celtique, S.A. (LU) | 2006-03-08 | — | — | EP | disclosed |
| EP-1627869-A1 | AMIDE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20060025402-A1 | Benzimidazolidinone derivatives as muscarinic agents | KELLY NICHOLAS M | 2006-02-02 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| WO-2005037832-A9 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | — | 2006-01-26 | — | — | WO | disclosed |
| EP-1613585-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1366036-B1 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1613601-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20060004004-A1 | Novel gamma secretase inhibitors | SCHERING CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050267102-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050256308-A1 | Spiro compounds, medicinal compositions containing the same and intermediates of the compounds | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1432420-A4 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245588-A1 | Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | disclosed |
| EP-1587511-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | Pharmacia & Upjohn Company LLC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005097768-A2 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
| US-6951849-B2 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1515724-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1562941-A2 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | Kosan Biosciences, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-20050171096-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1559707-A1 | SPIRO COMPOUNDS, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES OF THE COMPOUNDS | Dainippon Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| EP-1551962-A2 | MITOTIC KINESIN BINDING SITE | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-6911449-B2 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1542996-A2 | OCTAHYDRO-2-H-NAPHTHO 1,2-F INDOLE-4-CARBOXAMIDE DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6906053-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6900194-B1 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6890915-B2 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2005037832-A2 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-0942733-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-6881733-B1 | Serotonergic benzofurans | ELI LILLY AND COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-6881734-B2 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1515724-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1515951-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2005019206-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019205-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-20050043357-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-02-24 | — | — | US | disclosed |
| US-6858623-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
| US-6855832-B2 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6855512-B2 | Methods for identifying inhibitors of cytochrome P450RAI | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-0941093-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2005009988-A1 | HETEROARYL-TETRAHYDROPIPERIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009988-A1 | HETEROARYL-TETRAHYDROPIPERIDYL COMPOUNDS USEFUL FOR TREATING OR PREVENTING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-02-03 | — | — | WO | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004866-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE, S.A. (LU) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009799-A1 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
| WO-2005000775-A2 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| EP-0941092-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2004-12-29 | — | — | EP | disclosed |
| EP-0942732-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS | MERCK SHARP & DOHME (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-6818775-B2 | TREATMENT OF SKIN-RELATED DISEASES OR PREVENTION OF CERTAIN UNDESIRED SIDE EFFECTS OF ADMINISTERED RETINOIDS | ALLERGAN, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6809094-B2 | N-FUSED HETERCYCLO-1,4- OR -1,5- DIAZABICYCLO DERIVATIVES; NICOTINIC RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM (CNS) | PFIZER INC | 2004-10-26 | — | — | US | disclosed |
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2004089942-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209874-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | SHEPPECK JAMES E (US) | 2004-10-21 | — | — | US | disclosed |
| WO-2004089307-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO. INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1204660-B1 | SEROTONERGIC BENZOTHIOPHENES | LILLY CO ELI (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004087064-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087050-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040204416-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| EP-1345603-A4 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6787540-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ASTHMA, OSTEOPOROSIS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| EP-0923530-B1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS | BAYER AG (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-08-26 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040152708-A1 | Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same | KOSAN BIOSCIENCES, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1436298-A1 | HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6762184-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040132693-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-07-08 | — | — | US | disclosed |
| EP-1434769-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | JOHNSON ALAN T (US) | 2004-07-01 | — | — | US | disclosed |
| EP-1432707-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432420-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | Acadia Pharmaceuticals Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004043954-A2 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | KOSAN BIOSCIENCES INCORPORATED (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | BEARD RICHARD L (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-0915825-B1 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1042313-B1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1406901-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6720319-B2 | ((1-(4-CYANO-1-(2-MORPHOLIN-4-YL-ETHYL)-PIPERIDIN-4 -YLCARBAMOYL)- 2-CYCLOHEXYL-ETHYLAMINO) -MORPHOLIN-4-YL-METHYLENE)- CARBAMIC ACID ISOBUTYL ESTER; CATHEPSINS S, K, F, L AND B; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6720425-B2 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| US-20040067931-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004026248-A2 | OCTAHYDRO-2-H-NAPHTHO[1,2-F] INDOLE-4-CARBOXAMIDE DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-6713647-B2 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| EP-1388534-A2 | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | Allergan, Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003105855-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACIUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| EP-1366036-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | KLEIN ELLIOTT S (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6653483-B1 | Skin, neurodegenerative and cardiovascular disorders; anticarcinogenic, antiinflammatory, and antiproliferative agents | ALLERGAN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1117628-B1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN INC (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030203927-A1 | Thrombin receptor antagonists | SCHERING CORPORATION | 2003-10-30 | — | — | US | disclosed |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | ALLERGAN SALES, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6613765-B1 | Administering compounds such as 2-(1-(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4 -triazolo)methyl)morpholine; sustained release antidepressants with side effect reduction | MERCK SHARP & DOHME LIMITED | 2003-09-02 | — | — | US | disclosed |
| US-6613917-B1 | Retinoid agonist, antagonist or negative hormone-like biological activity | ALLERGAN, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| EP-0931786-B1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6603019-B2 | Phenylacetic or heteroarylacetic acid derivatives, retinoic acid inducible enzyme, used to treat diseases responsive to retinoids | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
| US-20030130273-A1 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1322631-A2 | METHODS OF PROVIDING AND USING COMPOUNDS ( RETINOIDS ) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030119837-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | PFIZER INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030100545-A1 | Benzimidazolidinone derivatives as muscarinic agents | ACADIA PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003035060-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6555690-B2 | 4-((5,5-dimethyl-5,6,7,8-tetrahydro-8-hydroxynaphthalen-2 -yl)carbonyloxy)benzoic acid, benzyl ester for example; receptor subtype selectivity for side effect reduction | ALLERGAN, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003033501-A1 | HIMBACINE ANALOGUES AS THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003028650-A2 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003029200-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6531599-B2 | RAI=retinoic acid inducible; for example, 4-((8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro(2H-1-benzopyran-2,1' -cyclopropane)-6-yl) ethynyl)-2-fluoro-benzoic acid; use treating diseases responsive to retinoids | ALLERGAN SALES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| EP-0853610-B1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6525052-B2 | Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6521624-B1 | Prevention or amelioration of toxicity or undesired side effect caused by a retinoid compound | ALLERGAN, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6511994-B2 | For prophylaxis and therapy of infection by HIV and the treatment of AIDS | MERCK & CO., INC. | 2003-01-28 | — | — | US | disclosed |
| US-6500847-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER CORPORATION | 2002-12-31 | — | — | US | disclosed |
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1265848-A2 | AMINES SUBSTITUTED WITH A DIHYDRONAPHTHALENYL, CRHOMENYL, OR THIOCHROMENYL GROUP, AN ARYL OR HETEROARYL GROUP AND AN ALKYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6495552-B2 | TREATMENT OR PREVENTION OF THE DISEASES AND CONDITIONS WHICH RESPOND TO TREATMENT BY RETINOIDS AND OR WHICH IN HEALTHY MAMMALS, INCLUDING HUMANS, ARE CONTROLLED BY NATURAL RETINOIC ACID. | ALLERGAN, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020183285-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-05 | — | — | US | disclosed |
| US-6489354-B1 | IN PARTICULAR, THESE COMPOUNDS ARE USEFUL AS MODULATORS OF THE CHEMOKINE RECEPTORS CCR-3 AND/OR CCR-5 USEFUL IN THE TREATMENT AND PREVENTION OF ATOPIC CONDITIONS INCLUDING ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, AND ASTHMA | MERCK & CO., INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2002-11-21 | — | — | US | disclosed |
| US-6479486-B2 | ANTIDEPRESSANTS, ANALGESICS | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
| US-20020160986-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020156082-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ROLR, INC. | 2002-10-24 | — | — | US | disclosed |
| US-20020156054-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6469028-B1 | ARYL-SUBSTITUTED AND ARYL AND (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE, AND 5,6-DIHYDRONAPHTHALENE DERIVATIVES | ALLERGAN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-6465663-B2 | ETHYL (E)-4-(2-(5,6-DIHYDRO-5,5-DIMETHYL-NAPHTHALEN-8(7H)-ONE-2 -YL)ETHENYL)BENZOATE AND ETHYL (E)-4-(2-(5,6-DIHYDRO-5,5-DIMETHYL-8-(PHENYLTHIO)-NAPHTHALENYL)ETHENYL) BENZOATE | ALLERGAN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020132796-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-09-19 | — | — | US | disclosed |
| EP-0790974-B1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER AG (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1228055-A1 | DIHYDROAMINOBENZO[B]- AND [C]FURANS AS RETINOID-LIKE AGENTS | Allergan Sales, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| US-20020099038-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2002-07-25 | — | — | US | disclosed |
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
| US-20020086871-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | O'NEILL BRIAN THOMAS (US) | 2002-07-04 | — | — | US | disclosed |
| EP-1219622-A2 | Pharmaceutical compositions for CNS and other disorders | Pfizer Products Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1217994-A2 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Bayer Aktiengesellschaft (DE) | 2002-07-03 | — | — | EP | disclosed |
| US-6403638-B1 | COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME | ALLERGAN SALES, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6399774-B1 | SKIN DISORDERS; CONTROLLING CELL PROLIFERATIVE | ALLERGEN SALES, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1171122-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1204659-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204660-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6387892-B1 | SKIN DISORDERS; ANTIPROLIFERATIVE AGENT | ALLERGAN SALES, INC. | 2002-05-14 | — | — | US | disclosed |
| US-6387951-B1 | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS | ALLERGAN SALES, INC. | 2002-05-14 | — | — | US | disclosed |
| US-6380256-B1 | FOR THERAPY OF DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6372764-B1 | ANTIINFLAMMATORY AGENTS AND AIDS TREATMENT | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6369225-B1 | ENZYME INHIBITORS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6369261-B1 | CYCLOPROPYLBENZENE DERIVATIVE OF ACIDS OR ESTERS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6362201-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | MERCK & CO., INC. | 2002-03-26 | — | — | US | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| US-6355806-B1 | REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, AGENTS FOR TREATING SKIN-RELATED DISEASES | ALLERGEN SALES, INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6344561-B2 | TREATMENT OF SKIN DISORDERS, INFLAMMATION, NERVE SYSTEM DISORDERS, CANCER | ALLERGAN SALES, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303785-B1 | SUBSTITUTED N-CYCLOPROPYLTETRAHYDROISOQUINOLINES | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| EP-1140085-A1 | AZABICYCLOALKANES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140768-A1 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | Bayer Aktiengesellschaft (DE) | 2001-10-10 | — | — | EP | disclosed |
| EP-0880528-B1 | SPIRO-KETAL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070668-A2 | AMINES SUBSTITUTED WITH A DIHYDRONAPHTHALENYL, CRHOMENYL, OR THIOCHROMENYL GROUP, AN ARYL OR HETEROARYL GROUP AND AN ALKYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6291677-B1 | FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES AND KERATINIZATION AND HYPERPROLIFERATIVE DISORDERS OF SKIN | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6288063-B1 | ANTIARTHRITIC AGENTS; AUTOIMMUNE, NERVOUS SYSTEM, BRAIN, CARDIOVASCULAR, AND RESPIRATORY SYSTEM DISORDERS | BAYER CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6271230-B1 | ADMINISTERING NEUROKININ RECEPTOR ANTAGONIST | MERCK SHARP & DOHME LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-1117628-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6248755-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1009405-A4 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6228848-B1 | 3-(1-PROPEN-3-OXO)-5,6-DIHYDRONAPHTHALENE DERIVATIVES; SIDE EFFECT REDUCTION | ALLERGAN, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6225314-B1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-6225320-B1 | TREATMENT OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTTHERPETIC NEURALGIA | MERCK SHARP & DOHME LTD. (GB) | 2001-05-01 | — | — | US | disclosed |
| US-20010000511-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2001-04-26 | — | — | US | disclosed |
| US-6218128-B1 | DRUG SCREENING FOR INVERSE AGONIST BY MONITORING BINDING OF TWO POLYPEPTIDES HAVING SPECIFIC DOMAINS IN PRESENCE OF TEST COMPOUND | ALLERGAN SALES, INC. | 2001-04-17 | — | — | US | disclosed |
| WO-2001022951-A2 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-05 | — | — | WO | disclosed |
| EP-1087761-A2 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES | Bayer Aktiengesellschaft (DE) | 2001-04-04 | — | — | EP | disclosed |
| US-6207701-B1 | AS ANTI-ANGIOGENIC, ANTI-ARTHRITIC, ANTI-INFLAMMATORY, ANTI-RETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC AGENTS | ABBOTT LABORATORIES | 2001-03-27 | — | — | US | disclosed |
| EP-1082295-A1 | SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-2001012618-A1 | DIHYDROAMINOBENZO[B]- AND [C]FURANS AS RETINOID-LIKE AGENTS | ALLERGAN SALES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6187933-B1 | BIND TO RETINOID RECEPTORS; TREATING SKIN DISORDERS | ALLERGAN SALES, INC. | 2001-02-13 | — | — | US | disclosed |
| WO-2001009126-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6172077-B1 | TACHYKININ INHIBITORS; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIEMETICS; NEURALGIA, HEADACHES | MERCK SHARP & DOHME LTD. (GB) | 2001-01-09 | — | — | US | disclosed |
| EP-0756481-B1 | 17$g(b)-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO INC (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6166037-A | Pyrrolidine and piperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6166082-A | Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6156749-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
| US-6147224-A | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN SALES, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1042313-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | Allergan Sales, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6127365-A | Spiro-ketal derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| US-6117987-A | ANIMAL GROWTH REGULATOR; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051610-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051609-A1 | 3-ALKYL SUBSTITUTED PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051607-A1 | 3-CYCLOPROPYL AND 3-CYCLOBUTYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-6114315-A | ORAL ADMINISTERING; SIDE EFFECT REDUCTION | MERCK SHARP & DOHME LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| WO-2000050017-A2 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-08-31 | — | — | WO | disclosed |
| EP-1031349-A1 | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases | Bayer Aktiengesellschaft (DE) | 2000-08-30 | — | — | EP | disclosed |
| US-6100256-A | ORALLY ADMINISTERING AN ORALLY ACTIVE, LONG ACTING, CENTRAL NERVOUS SYSTEM-PENETRANT NK-1(NEUROKININ-1, SUBSTANCE P) RECEPTOR ANTAGONIST; FOR PATIENT WHO IS NON-RESPONSIVE TO, OR FOR WHOM ANTIPSYCHOTIC AGENTS ARE CONTRAINDICATED | MERCK SHARP & DOHME LTD. (GB) | 2000-08-08 | — | — | US | disclosed |
| US-6096729-A | Use of NK-1 receptor antagonists for treating amnestic disorders | MERCK SHARP & DOHME LTD. (GB) | 2000-08-01 | — | — | US | disclosed |
| US-6093838-A | FOR TREATING SKIN-RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, ECZEMA | ALLERGAN SALES, INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1019410-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2000-07-19 | — | — | EP | disclosed |
| US-6090819-A | Use of NK-1 receptor antagonists for treating mania | MERCK SHARP & DOHME, LTD. (GB) | 2000-07-18 | — | — | US | disclosed |
| US-6090810-A | SIDE EFFECT REDUCTION | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000040539-A1 | USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-07-13 | — | — | WO | disclosed |
| US-6087348-A | TREATING PHYSIOLOGICAL DISORDERS OR PSYCHOLOGICAL DISORDERS WITH NEUROKININ 1 (SUBSTANCE P) RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ORAL ONCE-A-DAY MEDICAMENT | MERCK SHARP & DOHME LTD. (GB) | 2000-07-11 | — | — | US | disclosed |
| WO-2000038680-A1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-1009405-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-1001779-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-05-24 | — | — | EP | disclosed |
| US-6060469-A | Spiro-piperidine derivatives and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-05-09 | — | — | US | disclosed |
| US-6051731-A | TREATING SKIN DISORDERS, CANCERS, EYE DISORDERS, CARDIOVASCULAR DISORDERS, ELIMINATE OR REDUCE SIDE EFFECTS OF RETINOIDS, OR TO TREAT RETINOID OR VITAMIN A OVERDOSE OR POISONING | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-2000020370-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| EP-0991636-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan Sales, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0989987-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-05 | — | — | EP | disclosed |
| US-6046195-A | Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-04-04 | — | — | US | disclosed |
| EP-0977758-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | disclosed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5998471-A | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998655-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN, INC. | 1999-12-07 | — | — | US | disclosed |
| WO-1999061413-A1 | SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5977104-A | Use of NK-1 receptor antagonists for treating bipolar disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| US-5968795-A | ANTIARTHRITIC/ANTIINFLAMMATORY/ANTIMETASTASIS/ANTIFERTILITY/ ANTITUMOR AGENTS; FOR TREATMENT OF ORAL/CARDIOVASCULAR DISEASES, VISION DEFECTS, PROTEINURIA, DYSTROPHOBIC EPIDERMOLYSIS, BULLOSA, BONE/NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5958954-A | 2,2-DIALKYL-4-ARYL-SUBSTITUTED BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES | ALLERGAN SALES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0942733-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942731-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942735-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SCHIZOPHRENIC DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942729-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING STRESS DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942734-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942730-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942728-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0941093-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME LTD. (GB) | 1999-09-15 | — | — | EP | disclosed |
| EP-0941092-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-15 | — | — | EP | disclosed |
| US-5952315-A | TREATING PHYSIOLOGICAL DISORDERS, DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS ANXIETY, DEPRESSION AND PSYCHOSIS WITH AN ANTIDEPRESSANT | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5952345-A | RETINOID ACID RECEPTOR ANTAGONIST; A DERIVATIVES OF ARYL-SUBSTITUTED AND ARYL (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE; PREVENTING TOXICITY OR SIDE EFFECTS CAUSED BY RETINOIDS OR VITAMIN A | ALLERGAN SALES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5952330-A | A HETEROCYCLE-ALKYLMORPHOLINES FOR TREATING PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | disclosed |
| US-5929054-A | Use of NK-1 receptor antagonists for treating sexual dysfunctions | MERCK SHARP (GB) | 1999-07-27 | — | — | US | disclosed |
| EP-0929554-A1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-07-21 | — | — | EP | disclosed |
| US-5925627-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5925637-A | ENZYME INHIBITORS AS ANTIARTHRITIC AGENTS OR CARDIOVASCULAR DISORDERS | BAYER CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5919781-A | Use of NK-1 receptor antogonists for treating substance use disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-06 | — | — | US | disclosed |
| EP-0923530-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0915825-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0799231-B1 | SPIROKETAL DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1999009984-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5877207-A | SKIN DISORDERS; ANTICARCINOGENIC AGENTS | ALLERGAN SALES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1999007374-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007373-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MANIA | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007375-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING AGGRESSIVE BEHAVIOUR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| US-5863915-A | ENZYME INHIBITORS FOR BONES AND JOINTS | BAYER CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998054187-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
| EP-0880528-A1 | SPIRO-KETAL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0756481-A4 | 17-g(b)-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO INC (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998049170-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
| US-5808124-A | BINDING TO RETINOID RECEPTORS | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| US-5808083-A | Acetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| US-5789434-A | ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION | BAYER CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0853610-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5776699-A | MEASURING GENE EXPRESSION | ALLERGAN, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5773594-A | TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF OTHER RETINOIDS | ALLERGAN (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1998024442-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024444-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024445-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SCHIZOPHRENIC DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024439-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEVERE ANXIETY DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024447-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024443-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024441-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024440-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING STRESS DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024438-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| US-5763635-A | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-06-09 | — | — | US | disclosed |
| US-5760276-A | TREATING SKIN DISORDERS, REDUCING SIDE EFFECTS OF RETINOIDS | ALLERGAN (US) | 1998-06-02 | — | — | US | disclosed |
| US-5747542-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN (US) | 1998-05-05 | — | — | US | disclosed |
| US-5741896-A | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1998013369-A1 | SPIRO-AZACYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| US-5728695-A | TACHYKININ ANTAGONISTS USEFUL IN TREATMENT OR PREVENTION OF PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA | MERCK SHARP & DOHME LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997048672-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997043239-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY 2-SUBSTITUTED-4-(4-SUBSTITUTEDPHENYL)-4-OXOBUTYRIC ACIDS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0800517-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0799231-A1 | SPIROKETAL DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1997-10-08 | — | — | EP | disclosed |
| EP-0790974-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | Bayer Corporation (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997030055-A1 | SPIRO-KETAL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| US-5648514-A | Substituted acetylenes having retinoid-like biological activity | ALLERGAN (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1997019084-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| US-5618931-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS | ALLERGAN | 1997-04-08 | — | — | US | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0756481-A1 | 17$g(b)-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO. INC. (US) | 1997-02-05 | — | — | EP | disclosed |
| US-5563263-A | EPOXIDATION CATALYSTS | HOECHST CELANESE CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020197-A1 | SPIROKETAL DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
| US-5525608-A | ANTIACNE AGENT, SKIN DISORDERS, GLANDULAR DISORDERS | MERCK & CO., INC. (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1996015096-A1 | SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS | BAYER CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996008311-A1 | D4-SYMMETRIC PORPHYRIN-BASED CATALYSTS, PROCESSES FOR PREPARING SAME, AND PROCESSES FOR USING SAME | HOECHST CELANESE CORPORATION (US) | 1996-03-21 | — | — | WO | disclosed |
| WO-1995028928-A1 | 17β-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1995028928-A1 | 17β-ARYL-4-AZA-STEROID DERIVATIVES | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296226-A1 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | NFE2L2 1736/4885POLB 3055/4885KDM4E 1486/4885 |
| US-20100331369-A1 | Therapeutic Agents Useful for Treating Pain | GRIN1, GRIK1, GRIN2B | NFE2L2 1783/4885POLB 3108/4885KDM4E 3889/4885 |
| US-20070072924-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | NFE2L2 727/4885POLB 4002/4885KDM4E 2412/4885 |
| US-10081603-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | NFE2L2 2710/4885POLB 2003/4885KDM4E 157/4885 |
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | NFE2L2 2710/4885POLB 460/4885KDM4E 2213/4885 |
| US-20080070948-A1 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS | CHRM4, CHRM1, CHRM2 | NFE2L2 4338/4885POLB 4508/4885KDM4E 1870/4885 |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | NFE2L2 1690/4885POLB 3761/4885KDM4E 3058/4885 |
| US-20150344421-A1 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives | VDR, CYP24A1, CYP2R1 | NFE2L2 2355/4885POLB 3464/4885KDM4E 3193/4885 |
| US-20060128755-A1 | Amide derivative | NR0B1, NR0B2, NR1I3 | NFE2L2 2849/4885POLB 367/4885KDM4E 2406/4885 |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | NFE2L2 792/4885POLB 1579/4885KDM4E 2384/4885 |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | NFE2L2 2260/4885POLB 3288/4885KDM4E 3772/4885 |
| US-20230124468-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | NFE2L2 2680/4885POLB 1970/4885KDM4E 3111/4885 |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | NFE2L2 3182/4885POLB 3721/4885KDM4E 1577/4885 |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | NFE2L2 828/4885POLB 1610/4885KDM4E 4716/4885 |
| US-20140171410-A1 | Batrachotoxin Analogues, Compositions, Uses, and Preparation Thereof | TRPV1, TRPV4, TRPV5 | NFE2L2 3457/4885POLB 4178/4885KDM4E 2785/4885 |
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | NFE2L2 812/4885POLB 4746/4885KDM4E 3606/4885 |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | NFE2L2 1564/4885POLB 783/4885KDM4E 292/4885 |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | NFE2L2 3030/4885POLB 3856/4885KDM4E 3066/4885 |
| US-20060004004-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | NFE2L2 1631/4885POLB 577/4885KDM4E 2824/4885 |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | HCAR1, HCAR2, FFAR1 | NFE2L2 2272/4885POLB 3369/4885KDM4E 4824/4885 |
| US-20190276472-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | NFE2L2 1670/4885POLB 2832/4885KDM4E 1514/4885 |
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | NFE2L2 1092/4885POLB 4733/4885KDM4E 925/4885 |
| US-20150111921-A1 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | TEK, CTTN, FLT1 | NFE2L2 3757/4885POLB 4063/4885KDM4E 4067/4885 |
| US-20140038936-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | NFE2L2 1681/4885POLB 971/4885KDM4E 2889/4885 |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | NFE2L2 938/4885POLB 1482/4885KDM4E 2750/4885 |
| US-20140171418-A1 | Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones | NQO2, ALPI, DHPS | NFE2L2 1770/4885POLB 446/4885KDM4E 2660/4885 |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | NFE2L2 104/4885POLB 4294/4885KDM4E 1364/4885 |
| US-20050176720-A1 | Pharmaceutical composition for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | NFE2L2 4800/4885POLB 2928/4885KDM4E 4027/4885 |
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | PIK3CD, PIK3CA, PIK3C2B | NFE2L2 1773/4885POLB 1760/4885KDM4E 1844/4885 |
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | OPRL1, OPRK1, COMT | NFE2L2 770/4885POLB 2559/4885KDM4E 4476/4885 |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NFE2L2 1754/4885POLB 3788/4885KDM4E 657/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | NFE2L2 1092/4885POLB 4733/4885KDM4E 925/4885 |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | NFE2L2 1272/4885POLB 2468/4885KDM4E 3097/4885 |
| US-12077526-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | MDM2, TP53, TP53BP1 | NFE2L2 547/4885POLB 874/4885KDM4E 3104/4885 |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | NFE2L2 1564/4885POLB 783/4885KDM4E 292/4885 |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NFE2L2 1754/4885POLB 3788/4885KDM4E 657/4885 |
| US-11945808-B2 | Substituted cyclohexyl compounds as NOP inhibitors | OPRL1, OPRK1, NOP56 | NFE2L2 855/4885POLB 360/4885KDM4E 4470/4885 |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | BHMT, BHMT2, GNMT | NFE2L2 335/4885POLB 1728/4885KDM4E 2868/4885 |
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | NFE2L2 1206/4885POLB 3043/4885KDM4E 4200/4885 |
| US-20190127347-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | NFE2L2 1564/4885POLB 783/4885KDM4E 292/4885 |
| US-10093629-B2 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors | RORC, RORB, RORA | NFE2L2 2116/4885POLB 3368/4885KDM4E 2167/4885 |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | NFE2L2 3634/4885POLB 1289/4885KDM4E 2301/4885 |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | NFE2L2 2680/4885POLB 1970/4885KDM4E 3111/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | NFE2L2 271/4885POLB 242/4885KDM4E 3661/4885 |
| US-20150099729-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | NFE2L2 1396/4885POLB 4716/4885KDM4E 2511/4885 |
| US-11992489-B2 | Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | NFE2L2 495/4885POLB 1968/4885KDM4E 1145/4885 |
| US-20130065877-A1 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF | PRLHR, TACR1, TACR2 | NFE2L2 1449/4885POLB 2674/4885KDM4E 1278/4885 |
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP26 | NFE2L2 3460/4885POLB 281/4885KDM4E 3234/4885 |
| US-20040167182-A1 | Hydroxamic acid and amide compounds and their use as protease inhibitors | MMP1, MMP3, MMP13 | NFE2L2 1554/4885POLB 3370/4885KDM4E 679/4885 |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | NFE2L2 808/4885POLB 2018/4885KDM4E 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.